Development of Antitumor Drugs Targeting c-MYC Pu27 and KRAS G-Quadruplexes

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Traditional chemotherapy faces challenges like side effects and drug resistance.
• Targeting G-quadruplex structures offers a promising alternative for cancer treatment.
• The c-MYC and KRAS oncoproteins are frequently implicated in cancer development.

Purpose of the Study:

• To synthesize and evaluate novel pyrazolo[4,3-c]quinoline derivatives as ligands for G-quadruplex DNA.
• To investigate the potential of these compounds as anticancer agents by targeting c-MYC and KRAS G-quadruplexes.
• To assess the in vitro and in vivo efficacy of the lead compound PQ32.

Main Methods:

• Synthesis of a novel series of pyrazolo[4,3-c]quinoline compounds.
• G-quadruplex stabilization assays using thermal melting (ΔTm).
• In vitro antiproliferative assays (IC50), cell cycle analysis, apoptosis assays, and gene expression analysis (c-MYC, KRAS).
• In vivo efficacy evaluation in a xenograft mouse model.

Main Results:

• Compound PQ32 demonstrated significant stabilization of c-MYC Pu27 and KRAS G-quadruplexes.
• PQ32 inhibited tumor cell proliferation with an IC50 of approximately 1.00 μM.
• PQ32 induced G2 cell cycle arrest and apoptosis, and suppressed c-MYC and KRAS gene expression.
• PQ32 showed significant tumor growth inhibition in a xenograft model, comparable to cisplatin.

Conclusions:

• Pyrazolo[4,3-c]quinoline derivatives, particularly PQ32, are effective G-quadruplex stabilizers with potent anticancer activity.
• Targeting multiple G-quadruplexes with quinoline-based ligands represents a viable anticancer therapeutic strategy.
• PQ32 warrants further investigation as a potential novel chemotherapeutic agent.